Mark Alles Founder of TORL BioTherapeutics Backed byGoldman SachsMarcus Goldman SourcesTORL BioTherapeutics Announces 58 Million Oversubscribed Series B-2 Financing to Advance the Clinical Development of its Novel Antibody-Drug Conjugate (ADC) Oncology Pipeline — 2024-04 Browse all founders · Browse investors
